Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy
Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Oliver Sartor(Mayo Clinic), Osama Mosalem(Mayo Clinic in Florida), Geoffrey B. Johnson(Boston University), Skye Buckner‐Petty(Mayo Clinic in Arizona), Jaxon Quillen(Mayo Clinic in Arizona), Miguel Muniz(Mayo Clinic in Arizona), Daniel S. Childs(Mayo Clinic in Arizona)
Cited by 3
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k